ViatrisHAM:VIA -1.15%60 Dividend Payout Ratio is 0.20 as of Mar. 2026, which is 18% above its 10-year median of 0.17. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.58 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 444 Drug Manufacturers companies, Viatris ranks better than 76.13% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Viatris's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.20.
The historical rank and industry rank for Viatris's Dividend Payout Ratio or its related term are showing as below:
HAM:VIA'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14 Med: 0.17 Max: 0.2
Current: 0.2
During the past 13 years, the highest Dividend Payout Ratio of Viatris was 0.20. The lowest was 0.14. And the median was 0.17.
HAM:VIA's Dividend Payout Ratio is ranked better than 76.13% of 444
companies
in the Drug Manufacturers industry
Industry Median: 0.375
vs HAM:VIA: 0.20
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Viatris was 62.40% per year. The lowest was 0.00% per year. And the median was 14.05% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Viatris (HAM:VIA) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Viatris Dividend Payout Ratio Related Terms
Viatris Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Viatris's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Viatris's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Viatris's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Dividend Payout Ratio of 0.20 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Viatris and its competitors. This is 18% above median its historical median of 0.17. Over the past decade, Viatris' Dividend Payout Ratio has ranged from 0.14 to 0.20. According to the industry distribution chart, Viatris ranks #106 out of 444 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Viatris' Dividend Payout Ratio too high?
Viatris' current Dividend Payout Ratio of 0.20 is 18% above median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 0.20. The Drug Manufacturers industry median Dividend Payout Ratio is 0.38. Viatris' value of 0.20 is 46.7% below this industry median. Based on the distribution chart, Viatris ranks #106 out of 444 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Dividend Payout Ratio compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #106 out of 444 companies for Dividend Payout Ratio. This places Viatris in the top 24% of its industry — outperforming the majority of peers. The industry median Dividend Payout Ratio is 0.38. Viatris' value of 0.20 is 46.7% below this benchmark. Historically, Viatris' own Dividend Payout Ratio has ranged from 0.14 to 0.20 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 0.38, Viatris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 444 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current Dividend Payout Ratio of 0.20 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Dividend Payout Ratio is 0.20, which is 18% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.58, compared to a current price of €14.10 — trading 47.2% above its estimated fair value. The current Dividend Payout Ratio is 0.20, which is 18% above median its 10-year median of 0.17 and 46.7% below the Drug Manufacturers industry median of 0.38. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Dividend Payout Ratio is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.10 is trading 47.2% above its estimated GF Value™ of €9.58.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Dividend Payout Ratio: 0.20 (18% above median its 10-year median of 0.17)
GF Value™: €9.58 vs. price of €14.10 (47.2% above fair value)
Industry Position: 46.7% below the Drug Manufacturers median (#106 of 444)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for HAM:VIA
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
